Drug-eluting stent thrombosis

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 1, 2009, Pages 45-52

  Stähli, Barbara E ^a   Camici, Giovanni G ^a   Tanner, Felix C ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute coronary syndrome; Drug eluting stent; Re endothelialization; Stent thrombosis; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; PRASUGREL; RAPAMYCIN; THROMBOPLASTIN; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; CELL PROLIFERATION; CORONARY ARTERY CONSTRICTION; DRUG ELUTING STENT; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; RISK ASSESSMENT; STENT THROMBOSIS; THROMBOGENESIS; THROMBOGENICITY; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 67650322291     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708096280     Document Type: Review

References (64)

1. Aoki, J., Serruys, P.W., van Beusekom, H., Ong, A.T.L., McFadden, E.P., Sianos, G. et al. (2005) Endothelial progenitor cell capture by stents coated with antibody against CD34, The healing-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man). J Am Coll Cardiol 45: 1574-1579.
2. Babapulle, M.N., Joseph, L., Bélisle, P., Brophy, J.M. and Eisenberg, M.J. (2004) A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364: 583-591.
3. Beohar, N., Davidson, C.J., Kip, K.E., Goodreau, L., Vlachos, H.A., Meyers, S.N. et al. (2007 May 9) Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (18): 1992-2000.
4. Blindt, R., Vogt, F., Astafieva, I., Fach, C., Hristov, M., Krott, N. et al. (2006) A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol 47: 1786-1795.
5. Butzal, M., Loges, S., Schweizer, M., Fischer, U., Gehling, U.M., Hossfeld, D.K. et al. (2004) Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Experimental Cell Reserach 300: 65-71.
6. Camenzind, E., Steg, G. and Wijns, W. (2007) Stent thrombosis late after implantation of first-generation drug-eluting stents. A cause for concern. Circulation 115: 1440-1455.
7. Camici, G.G., Steffel, J., Akhmedov, A., Schafer, N., Baldinger, J., Schulz, U. et al. (2006) Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation. A potential treatment strategy for drug-eluting stents. Circulation 114: 1512-1521.
8. Chen, T.-G., Chen, J.Z. and Wang, X.-X. (2006) Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 39: 117-125.
9. Creel, C.J., Lovich, M.A. and Edelman, E.R. (2000) Arterial paclitaxel distribution and deposition. Circ Res 86: 879-884.
10. Cutlip, D.E., Baim, D.S., Ho, K.K.L., Popma, J.J., Lansky, A.J., Cohen, D.J. et al. (2001) Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials. Circulation 103: 1967-1971.
11. Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C. et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369: 667-678.
12. de la Torre-Hernández, J.M., Alfonso, F., Hernández, F., Elizaga, J., Sanmartin, M., Pinar, E. et al. (2008) Drug-eluting stent thrombosis. Results from the Multicenter Spanish Registry ESTROFA. J Am Coll Cardiol 51: 1986-1990.
13. Doyle, B., Rihal, C.S., O'Sullivan, C.J., Lennon, R.J., Wiste, H.J., Bell, M. et al. (2007) Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 116: 2391-2398.
14. Eisenstein, E.L., Anstrom, K.J., Kong, D.F., Shaw, L.K., Tuttle, R.H., Mark, D.B. et al. (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 279: 159-168.
15. Farb, A., John, M., Acampado, E., Kolodgie, F.D., Prescott, M.F. and Virmani, R. (2002) Oral everolimus inhibits in-stent neointimal growth. Circulation 106: 2379-2384.
16. Farb, A., Burke, A.P., Kolodgie, F.D. and Virmani, R. (2003) Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108: 1701-1706.
17. Finn, A.V., Kolodgie, F.D., Harnek, J., Guerrero, L.J., Acampado, E., Tefera, K. et al. (2005) Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112: 270-278.
18. Finn, A.V., Joner, M., Nakazawa, G., Kolodgie, F., Newell, J., John, M.C. et al. (2007 a) Pathological correlates of late drug-eluting stent thrombosis. Strut coverage as a marker of endothelialization. Circulation 115: 2435-2441.
19. Finn, A.V., Nakazawa, G., Joner, M., Kolodgie, F.D., Mont, E.K., Gold, H.K. et al. (2007 b) Vascular responses to drug eluting stents. Importance of delayed healing. Arterioscler Thromb Vasc Biol 27: 1500-1510.
20. Flores-Ríos, X., Marzoa-Rivas, R., Abugattás-de Torres, J.P., Pinñón-Esteban, P., Aldama-López, G., Salgado-Fernández, J. et al. (2008) Late thrombosis of paclitaxel-eluting stents: Long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. Am Heart J 155: 648-653.
21. Garcia-Touchard, A., Burke, S.E., Toner, J.L., Cromack, K. and Schwartz, R.S. (2006) Zotarolimuseluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 27: 988-993.
22. Griese, D.P., Ehsan, A., Melo, L.G., Kong, D., Zhang, L., Mann, M.J. et al. (2003) Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts. Implications for cell-based vascular therapy. Circulation 108: 2710-2715.
23. Grines, C.L., Cox, D.A., Stone, G.W., Garcia, E., Mattos, L.A., Giambartolomei, A. et al. (1999) Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 341: 1949-1956.
24. Grines, C.L., Bonow, R.O., Casey, D.E., Gardner, T.J., Lockhart, P.B., Moliterno, D.J. et al. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 138: 652-655.
25. Grubel, P.A., DiChiara, J. and Tantry, US (2007) Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol 100(suppl): 18M-25M.
26. Hofma, S.H., van der Giessen, W.J., van Dalen, B.M., Lemos, P.A., McFadden, E.P., Sianos, G. et al. (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27: 166-170.
27. Holmes, D.R., Kereiakes, D.J., Laskey, W.K., Colombo, A., Ellis, S.G., Henry, T.D. et al. (2007) Thrombosis and drug-eluting stents. An objective appraisal. J Am Coll Cardiol 50: 109-118.
28. Hong, M.-K., Mintz, G.S., Lee, C.W., Park, D.-W., Park, K.-M., Lee, B.-K. et al. (2006) Late stent malapposition after drug-eluting stent implantation. An intravascular ultrasound analysis with long-term follow-up. Circulation 113: 414-419.
29. Iakovou, I., Schmidt, T., Bonizzoni, E., Ge, L., Sangiorgi, G.M., Stankovic, G. et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-2130.
30. Joner, M., Finn, A.V., Farb, A., Mont, E.K., Kolodgie, F.D., Ladich, E. et al. (2006) Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol 48: 193-202.
31. Kotani, J.-I., Awata, M., Nanto, S., Uematsu, M., Oshima, F., Minamiguchi, H. et al. (2006) Incomplete neointimal coverage of sirolimus-eluting stents. Angioscopic findings. J Am Coll Cardiol 47: 2108-2111.
32. Lagerqvist, B., James, S.K., Stenestrand, U., Lindbaöck, J., Nilsson, T., Wallentin, L. et al. (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356: 1009-1019.
33. Lüscher, T.F., Steffel, J., Eberli, F.R., Joner, M., Nakazawa, G., Tanner, F.C. et al. (2007) Drug-eluting stent and coronary thrombosis. Biological mechanisms and clinical implications. Circulation 115: 1051-1058.
34. Marroquin, O.C., Selzer, F., Mulukutla, S.R., Williams, D.O., Vlachos, H.A., Wilensky, R.L. et al. (2008) A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 358: 342-352.
35. Matter, C.M., Rozenberg, I., Jaschko, A., Greutert, H., Kurz, D., Wnendt, S. et al. (2006) Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48: 286-292.
36. Mauri, L., Hsieh, W.-H., Massaro, J.M., Ho, K.K.L., D'Agostino, R. and Cutlip, D.E. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356: 1020-1029.
37. McFadden, E.P., Stabile, E., Regar, E., Cheneau, E., Ong, A.T.L., Kinnaird, T. et al. (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364: 1519-1521.
38. Moreno, R., Fernández, C., Hernández, R., Alfonso, F., Angiolillo, D.J., Sabaté, M. et al. (2005) Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45: 954-959.
39. Muldowney, J.A., Stringham, J.R., Levy, S.E., Gleaves, L.A., Eren, M., Piana, R.N. et al. (2007) Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27: 400-406.
40. Nakazawa, G., Cheng, Q., Xu, X., Finn, A.V., Kolodgie, F.D. and Virmani, R. (2008) Drug-eluting stent implantation may not affect vasomotor function in early phase. J Am Coll Cardiol 11: 1123-1126.
41. Nebeker, J.R., Virmani, R., Bennett, C.L., Hoffmann, J.M., Samore, M.H., Alvarez, J. et al. (2006) Hypersensitivity cases associated with drug-eluting coronary stents. A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47: 175-181.
42. Ong, A.T.L., Hoye, A., Aoki, J., van Mieghem, C.A.G., Granillo, G.A.R., Sonnenschein, K. et al. (2005) Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45: 947-953.
43. Ormiston, J.A., Serruys, P.W., Regar, E., Dudek, D., Thuesen, L., Webster, M.W.I. et al. (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371: 899-907.
44. Parry, T.J., Brosius, R., Thyagarajan, R., Carter, D., Argentieri, D., Falotico, R. et al. (2005) Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injuried arteries. European Journal of Pharmacology 524: 19-29.
45. Pfisterer, M., Brunner-La Rocca, H.P., Buser, P.T., Rickenbacher, P., Hunziker, P., Mueller, C. et al. (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48: 2584-2591.
46. Qian, J.-Y., Zhang, F., Fan, B., Wang, Q.-B. and Ge, J.-B. (2008) A more than 2-year follow-up of incomplete apposition after drug-eluting stent implantation. Chinese Medical Journal 121: 498-502.
47. Sollott, S.J., Cheng, L., Pauly, R.R., Jenkins, G.M., Monticone, R.E., Kuzuya, M. et al. (1995) Taxol inhibits neointima smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 95: 1869-1876.
48. Spaulding, C., Daemen, J., Boersma, E., Cutlip, D.E. and Serruys, P.W. (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356: 989-997.
49. Staöhli, B.E., Camici, G.G., Steffel, J., Akhmedov, A., Shojaati, K., Graber, M. et al. (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH 2 kinase activation. Circ Res 99: 149-155.
50. Staöhli, B.E., Breitenstein, A., Akhmedov, A., Camici, G.G., Shojaati, K., Bogdanov, N. et al. (2007) Cardiac glycosides regulate endothelial tissue factor expression in culture. Arterioscler Thromb Vasc Biol 27: 2769-2776.
51. Steffel, J., Latini, R.A., Akhmedov, A., Zimmermann, D., Zimmerling, P., Luscher, T.F. et al. (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression. Implications for drug-eluting stent design. Circulation 112: 2002-2011.
52. Steffel, J., Luscher, T.F., Tanner, F.C. et al. (2006) Tissue factor in cardiovascular diseases. Molecular mechanisms and clinical implications. Circulation 113: 722-731.
53. Steffel, J. and Tanner, F.C. (2007) Biological effects of drug-eluting stents in the coronary circulation. Herz 32: 268-273.
54. Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M.C., Schoömig, A. et al. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370: 937-948.
55. Stone, G.W., Moses, J.W., Ellis, S.G., Schofer, J., Dawkins, K.D., Morice, M.C. et al. (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356: 998-1008.
56. Suzuki, T., Kopia, G., Hayashi, S.-I., Bailey, L.R., Llanos, G., Wilensky, R. et al. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104: 1188-1193.
57. Togni, M., Raöber, L., Cocchia, R., Wenaweser, P., Cook, S., Windecker, S. et al. (2007) Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120: 212-220.
58. Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T. et al. (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we be cautious? Circulation 109: 701-705.
59. Vogt, F., Stein, A., Rettemeier, G., Krott, N., Hoffmann, R., vom Dahl, J. et al. (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25: 1330-1340.
60. Windecker, S., Simon, R., Lins, M., Klauss, V., Eberli, F.R., Roffi, M. et al. (2005 a) Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization. The TiNOX Trial. Circulation 111: 2617-2622.
61. Windecker, S., Remondino, A., Eberli, F.R., Juni, P., Raöber, L., Wenaweser, P. et al. (2005 b) Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353: 653-662.
62. Win, H.K., Caldera, A.E., Maresh, K., Lopez, J., Rihal, C.S., Parikh, M.A. et al. (2007 May 9) EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (18): 2001-9.
63. Windecker, S. and Meier, B. (2007 Oct 23) Late coronary stent thrombosis. Circulation. 116 (17): 1952-65.
64. Wiviott, S.D., Braunwald, E., McCabe, C.H., Horvath, I., Keltai, M., Herrman, J.P. et al. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of randomised trial. Lancet 371: 1353-1363.